121 related articles for article (PubMed ID: 22257279)
21. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
[TBL] [Abstract][Full Text] [Related]
22. The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
Petrukhin L; Dangel J; Vanderveer L; Costalas J; Bellacosa A; Grana G; Daly M; Godwin AK
Cancer Res; 1997 Dec; 57(24):5480-4. PubMed ID: 9407954
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.
Figer A; Karasik YP; Baruch RG; Chetrit A; Papa MZ; Sade RB; Rizel S; Friedman E
Isr Med Assoc J; 2002 Oct; 4(10):759-62. PubMed ID: 12389335
[TBL] [Abstract][Full Text] [Related]
24. A gift or a yoke? Women's and men's responses to genetic risk information from BRCA1 and BRCA2 testing.
d'Agincourt-Canning L
Clin Genet; 2006 Dec; 70(6):462-72. PubMed ID: 17100990
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
Metcalfe KA; Mian N; Enmore M; Poll A; Llacuachaqui M; Nanda S; Sun P; Hughes KS; Narod SA
Breast Cancer Res Treat; 2012 Jun; 133(2):735-40. PubMed ID: 22240989
[TBL] [Abstract][Full Text] [Related]
26. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.
Gal I; Kimmel G; Gershoni-Baruch R; Papa MZ; Dagan E; Shamir R; Friedman E
Eur J Cancer; 2006 May; 42(8):1129-34. PubMed ID: 16624550
[TBL] [Abstract][Full Text] [Related]
27. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
[TBL] [Abstract][Full Text] [Related]
28. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Foulkes WD; Wong N; Brunet JS; Bégin LR; Zhang JC; Martinez JJ; Rozen F; Tonin PN; Narod SA; Karp SE; Pollak MN
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2465-9. PubMed ID: 9815648
[TBL] [Abstract][Full Text] [Related]
29. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
30. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
[TBL] [Abstract][Full Text] [Related]
31. Effects of individual and family functioning on interest in genetic testing.
Bowen DJ; Bourcier E; Press N; Lewis FM; Burke W
Community Genet; 2004; 7(1):25-32. PubMed ID: 15475668
[TBL] [Abstract][Full Text] [Related]
32. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
33. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
[TBL] [Abstract][Full Text] [Related]
34. Perceptions of genetic testing for cancer predisposition among Ashkenazi Jewish women.
Lewis MJ; Peterson SK
Community Genet; 2007; 10(2):72-81. PubMed ID: 17380056
[TBL] [Abstract][Full Text] [Related]
35. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
36. Managing self-responsibility through other-oriented blame: family accounts of genetic testing.
Arribas-Ayllon M; Sarangi S; Clarke A
Soc Sci Med; 2008 Apr; 66(7):1521-32. PubMed ID: 18222583
[TBL] [Abstract][Full Text] [Related]
37. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations.
Kelly KM; Senter L; Leventhal H; Ozakinci G; Porter K
Patient Educ Couns; 2008 Jan; 70(1):135-42. PubMed ID: 17988821
[TBL] [Abstract][Full Text] [Related]
38. Conditions and consequences of a BRCA mutation in young, single women of childbearing age.
Hamilton R; Hurley KE
Oncol Nurs Forum; 2010 Sep; 37(5):627-34. PubMed ID: 20797954
[TBL] [Abstract][Full Text] [Related]
39. Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease.
Brandt-Rauf SI; Raveis VH; Drummond NF; Conte JA; Rothman SM
Am J Public Health; 2006 Nov; 96(11):1979-88. PubMed ID: 17018815
[TBL] [Abstract][Full Text] [Related]
40.
Sarig K; Oxley S; Kalra A; Sobocan M; Fierheller CT; Sideris M; Gootzen T; Ferris M; Eeles RA; Evans DG; Quaife SL; Manchanda R
J Med Genet; 2024 Jun; 61(7):716-725. PubMed ID: 38575303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
